Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug candidate COMP360 is aimed at treating patients with depression. COMP360 uses a type of psychedelic substance called psilocybin, and it’s in the final stages of studies. Compass Pathways PLC (CMPS): What Will Come Out of FDA Review Meeting for Depression Drug Candidate COMP360? Pressmaster/Shutterstock.com On March 3, Compass Pathways PLC (NASDAQ:CMPS) representatives attended TD Cowen’s ...

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights Mar 24, 2026 7:30 AM Eastern Daylight Time Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights Share "COMP360 is shaping the future of mental healthcare, and we are moving the field of psychiatric medicine forward for the millions of people urgently needing better options. As the potential first classic psychedelic approved by the FDA, COMP360 is redefinin ...

Summary of COMPASS Pathways Conference Call Company Overview - **Company**: COMPASS Pathways (NasdaqGS:CMPS) - **Focus**: Development of COMP360 for treatment-resistant depression (TRD) Key Industry Insights - **Market Size**: - Major Depressive Disorder (MDD) affects approximately 23 million patients, with only about 13 million treated with existing FDA-approved products. - TRD specifically affects around 4 million patients, but less than 200,000 are currently treated with TRD-indicated products [12][13]. Core Points and Arguments - **COMP360 Data**: - Recent data indicates that COMP360 has the potential to redefine treatment durability and rapidity in TRD [7]. - A meeting with regulatory agencies is scheduled to discuss a rolling submission and review process for COMP360 [8][9]. - Anticipated completion of the New Drug Application (NDA) submission by late 2026 [9]. - **Regulatory Perspective**: - The FDA is interested in long-term data regarding the efficacy and safety of COMP360, particularly from the COMP006 study [11]. - The focus is on understanding the duration of effects from one or two doses and ensuring no new safety issues arise [11]. - **Commercial Strategy**: - The company aims to ensure broad access to COMP360 upon launch, with a focus on timely rescheduling by the FDA and state authorities [12][14]. - Current efforts are directed towards ensuring that 90% of the patient population is rescheduled within 30 days post-DEA approval [19]. - **Provider Engagement**: - Providers are primarily interested in the availability of psilocybin rather than logistical concerns about administration [22][27]. - COMPASS is working on establishing specific CPT codes for psychedelic treatments to ensure adequate reimbursement for providers [28][32]. - **Patient Population**: - Initial patients are expected to come from high-prescribing Spravato sites, but there is a significant untapped patient population that has not been treated with TRD products [42][43]. - The typical TRD patient has a long history of depression and has failed multiple treatments [47]. Additional Important Insights - **PTSD Research**: - Early data from a small study on PTSD shows promising results, with plans for a larger study underway [50][54]. - The company is confident in the effectiveness of COMP360 for PTSD based on patient narratives and existing research [51]. - **Financial Position**: - Recent financing has provided a runway into 2028, allowing the company to focus on execution and competition with Spravato [57][59]. - **Market Awareness**: - There is significant awareness and interest in COMP360 as the company approaches potential approval [48]. This summary encapsulates the key points discussed during the COMPASS Pathways conference call, highlighting the company's strategic focus, regulatory considerations, and market dynamics surrounding COMP360.

Investment in DraftKings - ARK added approximately 58,048 shares of DraftKings (DKNG) valued at around $1.48 million, with DraftKings holding 1.9% weightage in the ARK Blockchain & Fintech Innovation ETF and 1.05% in the ARK Next Generation Internet ETF [1] - DraftKings benefits from state-by-state legalization across the U.S., expanding its total addressable market, and is focusing on improving profitability through disciplined marketing spending and stronger customer retention metrics [1][5] - DraftKings receives a "Strong Buy" rating on Wall Street, with analysts seeing a potential upside of 45% from current levels if it hits its average price target of $36.41, and a high price target of $53 implies a potential surge of 110.7% over the next year [6] Investment in Robinhood - ARK purchased about 183,933 shares of Robinhood Markets (HOOD) worth roughly $15.12 million, with Robinhood holding 4.3% weightage in the ARK Blockchain & Fintech Innovation ETF and 4.8% in the ARK Next Generation Internet ETF [3] - Robinhood is valued at $69.4 billion and is diversifying its offerings beyond meme-stock trading, including options, retirement accounts, and credit cards [2] - Robinhood receives a "Moderate Buy" rating on Wall Street, with analysts seeing a potential upside of 63% from current levels if it hits its average price target of $125.65, and a high price target of $180 implies a potential surge of 133.5% over the next year [2] Investment in Cerus Corp. - ARK purchased 612,501 shares of Cerus Corp. (CERS) worth about $1.37 million, with Cerus holding 1.2% weightage in the ARK Genomic Revolution ETF and 0.30% in the ARK Innovation ETF [7] - Cerus specializes in pathogen reduction technology for blood safety, with its main product, the INTERCEPT Blood System, helping reduce harmful pathogens in blood components [8] - Cerus stock receives a "Moderate Buy" rating on Wall Street, with analysts seeing a potential upside of 159% from current levels if it hits its average and high price target of $5.00 [9] Investment in Compass Pathways - ARK bought roughly 100,264 shares of Compass Pathways (CMPS) valued at about $706,861, with Compass holding 1.88% in the ARK Genomic Revolution ETF [10] - Compass focuses on creating innovative mental health treatments, particularly COMP360, an investigational psilocybin-based therapy for treatment-resistant depression and PTSD [11] - Compass stock receives a "Strong Buy" rating on Wall Street, with analysts seeing a potential upside of 233% from current levels if it hits its average price target of $21.92, and a high price target of $70 implies a potential surge of 963.8% over the next year [12] Investment in Canton Strategic Holdings - ARK purchased 93,900 shares of Canton Strategic Holdings (CNTN) worth about $439,452, with Canton holding 0.19% weightage in the ARK Blockchain & Fintech Innovation ETF [13] - Canton Strategic Holdings has shifted its focus from a clinical-stage biotech company to managing a digital asset treasury centered on the Canton Network [14] - Small-cap companies like Canton can offer explosive upside if their business models scale successfully, aligning with ARK's strategy of identifying emerging disruptors [15]

COMPASS Pathways (NasdaqGS:CMPS) FY Conference Summary Company Overview - **Company**: COMPASS Pathways - **Ticker**: CMPS - **Focus**: Development of COMP360, a treatment for treatment-resistant depression (TRD) Key Highlights from Phase III Studies Study Designs - **Study 005**: Placebo-controlled, 25 mg COMP360 vs. placebo, 6-week primary endpoint measuring change in MADRS (Montgomery-Åsberg Depression Rating Scale) from baseline after a single administration - **Study 006**: Three arms (10 mg, 25 mg, and 1 mg psilocybin), with two initial administrations three weeks apart, also with a 6-week primary endpoint [2][4] Results - **Study 005**: - 3.6 point difference in MADRS at primary endpoint, statistically significant at all time points [3] - 40% of patients receiving a second administration achieved remission [4] - **Study 006**: - 3.8 point difference between 25 mg and 1 mg active comparator at week 6, statistically significant at all time points [4] Clinical Significance - A clinically meaningful benefit is defined as at least a 25% reduction in MADRS, with 25% of patients in Study 005 and nearly 40% in Study 006 achieving this [9] Incremental Benefits of Dosing - The second dose may provide nuanced benefits, potentially increasing remission rates rather than just mean population MADRS separation [5][6] - The consistency of results across multiple trials suggests a durable response to treatment [21][22] Patient Quality of Life - A 25% reduction in MADRS correlates to significant improvements in daily functioning and quality of life for TRD patients [26][31] Commercial Strategy - The 10 mg dose did not meet clinical relevance at six weeks, but is being explored in PTSD trials [62][65] - The 25 mg dose is the primary focus for launch due to its robust statistical significance [62] FDA Relationship and Regulatory Strategy - The company maintains a strong relationship with the FDA, emphasizing a thorough and robust development process for COMP360 [83][84] - The FDA has encouraged the submission of data on a rolling basis, which may expedite the approval process [88] Safety and Monitoring - The safety profile of COMP360 is favorable, with a low barrier for patients to try the treatment [112] - The treatment model aligns with existing psychiatric care frameworks, utilizing similar facilities and personnel as current treatments like SPRAVATO [124][125] Future Data and Analysis - Additional data on quality of life outcomes and secondary metrics will be analyzed and reported in upcoming conferences [72][73] - Real-world evidence post-approval will help refine patient profiles for predicting treatment response [105][106] Conclusion - COMPASS Pathways is positioned to potentially revolutionize treatment for TRD with COMP360, supported by promising clinical data and a proactive regulatory strategy. The focus on patient quality of life and safety further enhances its commercial viability.

Group 1 - The webinar is hosted by Stephen Schultz, Senior Vice President of Investor Relations for COMPASS Pathways [2] - The call is being recorded, indicating a formal update on the company's status [1] - Forward-looking statements will be made during the call, which are subject to risks and uncertainties [3]

Core Insights - Compass Pathways has made significant progress in its psilocybin therapy for treatment-resistant depression (TRD), achieving positive results in two Phase 3 trials and planning to submit a New Drug Application (NDA) to the FDA [2][5][6] Group 1: Clinical Trial Results - The second Phase 3 trial met its primary endpoint, demonstrating statistically significant results for the proprietary formulation COMP360 [5] - The trials involved over 1,000 participants, showcasing consistent and clinically meaningful effects, which is a notable achievement in the challenging field of TRD treatment [5] Group 2: Market Reaction - Following the announcement of the trial results, Compass Pathways' stock surged by over 50%, with a trading increase of 42.3% noted shortly after the news [3][6] - The positive trial outcomes have prompted investor interest, indicating a potential for continued stock growth pending FDA feedback [6] Group 3: Regulatory Steps - Compass has requested a meeting with the FDA and aims to submit the NDA for full approval by the end of the year, marking a critical step in the drug approval process [6]

Summary of COMPASS Pathways Update Webinar Company Overview - **Company**: COMPASS Pathways (NasdaqGS:CMPS) - **Focus**: Development of COMP360, a treatment for treatment-resistant depression (TRD) Key Industry Insights - **Market Need**: Over 4 million adults in the U.S. suffer from TRD annually, with a significant burden compared to major depressive disorder (MDD) [4][34] - **Current Treatments**: Only one approved medication for TRD (Spravato), which requires multiple treatments to achieve similar effects to COMP360 [6][35] - **Economic Burden**: Medication-treated MDD costs nearly $100 billion annually, with TRD patients accounting for almost 50% of these costs due to ineffective treatments [35] Clinical Trial Results - **Trials Conducted**: COMP005 and COMP006, both phase 3 trials for COMP360 - **Primary Endpoint Achievement**: COMP360 met primary endpoints with high statistical significance in three consecutive trials [5][6] - **Efficacy**: - In COMP005, 25% of patients achieved a clinically meaningful reduction in symptoms by week six, sustained through 26 weeks [5][21] - In COMP006, this figure increased to 39% [5][19] - **Rapid Onset**: Patients typically respond within one day of treatment, with durable effects observed [5][6][37] - **Safety Profile**: COMP360 demonstrated a well-tolerated safety profile, with serious adverse events (SAEs) of suicidal ideation below 1% [27][32] Regulatory and Commercial Strategy - **FDA Interaction**: Submitted data to the FDA and requested a meeting to discuss NDA filing strategy, including potential for rolling submission and expedited review [7][42] - **Launch Readiness**: Plans to be launch-ready by the end of the year, with ongoing preparations for commercial rollout [33][39] - **Market Positioning**: COMP360 is positioned to be a leading treatment option for TRD, with a differentiated profile compared to existing therapies [33][38] Additional Insights - **Patient Population**: Trials focused on a highly symptomatic, treatment-resistant population, with a mean MADRS score of 32 [12][13] - **Retreatment Rates**: Approximately 70% of patients in the 25 mg arm of COMP005 opted for retreatment, indicating a strong interest in ongoing treatment [85] - **Commercial Potential**: If approved, COMP360 could significantly change the treatment landscape for TRD, with potential blockbuster revenue given the current market dynamics [38][40] Conclusion - COMPASS Pathways is on track to potentially revolutionize the treatment of TRD with COMP360, addressing a significant unmet need in the mental health space while preparing for a strategic market entry.

Core Insights - Compass Pathways plc has successfully achieved the primary endpoint in the ongoing Phase 3 COMP006 trial, which is the second of two Phase 3 trials evaluating COMP360 for treatment-resistant depression [1] Group 1 - The trial is assessing two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin [1] - The primary endpoint focused on the difference in change, indicating a significant milestone in the trial's progress [1]

Core Insights - Compass Pathways plc is set to report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic formulation of psilocybin for treatment-resistant depression (TRD) [1] Group 1 - The company will disclose new clinical data from Part A and Part B of trial COMP005 and Part A of trial COMP006 [1]